Prostatype Genomics Sees Positive Growth in US Commercial Activities

Strategic Insights -

Prostatype Genomics, a Swedish genomics company, reports continued progress in its commercial activities in the United States. The number of American urologists using the company's Prostatype genomic test for risk classification of established prostate cancer has surpassed 10, with a growing number of tests being completed. The company has also secured a billing partner to manage reimbursement from Medicare and other healthcare insurance providers once the company's Medicare application is approved. Prostatype Genomics' commercial activities in the US are developing positively, with a strong focus on ensuring efficient and scalable integration of the test into the workflow of leading urology clinics and hospitals.

Key Takeaways:

  • Prostatype Genomics' commercial activities in the US continue to develop positively, with the number of selected American urologists using the company's Prostatype genomic test exceeding 10.
  • The company has engaged a billing partner to handle administration and financial flows linked to reimbursement from Medicare and other healthcare insurance providers.
  • Prostatype Genomics is in active dialogue with Medicare to deliver the remaining clarifications requested for the company's Medicare application.
  • The company has secured positive feedback from opinion leaders, which will facilitate a faster commercial uptake once Medicare approval is obtained.
  • The company's sales force will be expanded as soon as Medicare approval is obtained, in line with the previously communicated business plan.
  • Prostatype Genomics' CEO Fredrik Rickman stated that the company has established a network of leading American urologists with positions at renowned hospitals, who are essential for the company's continued commercial launch.
  • The company has a cost-effective billing partner solution in place to manage reimbursement from Medicare and other federal and private healthcare insurance providers.

Statistics:

  • The number of selected American urologists using Prostatype Genomics' genomic test for risk classification of established prostate cancer has surpassed 10.
  • Prostatype Genomics' prognostic genomic test Prostatype(r) has been commercially available in the United States since 2024.
  • The company has engaged a billing partner with multiple years of experience in managing reimbursement from Medicare and other federal and private healthcare insurance providers.

Sources:

  • Prostatype Genomics AB (2024) - Prostatype Genomics announces that the company's commercial activities in the U.S. continue to develop in a positive way
  • Prostatype Genomics AB - Reference to the company's website, with access date: [Not available]